Dr. Gordon B. Mills
The University of Texas MD Anderson Cancer Center
Department of Systems Biology
- Signal transduction in lymphocytes and breast and ovarian cancer cells
Our laboratory has made significant contributions to the understanding of ovarian tumorigenesis, including the identification and development of lysophosphatidic acid (LPA) as a possible marker for early-stage ovarian cancer and as a potential target for therapy. We have also played a major role in the understanding of the genetic aberrations in the phosphatidylinositol 3 kinase/PTEN/AKT pathway forwarding this cascade as a major target for therapy in multiple different cancers.
Our research program is aimed at identifying the underlying genetic aberrations that occur in cancer (breast, ovarian, lung and prostate) and determining how they contribute to tumorigenesis. These observations should translate into novel indications of prognosis, response to therapy and outcome. Importantly this should lead to new therapies having a major impact on cancer.
A tutorial in my laboratory would provide experience in novel technologies, genomics, DNA arrays, transcriptional profiling, proteomics as well as experience the molecular biology and biochemistry of signal transduction related to tumor initiation, progression, programmed cell death, oncogenes and tumor suppressor genes.
Previous students from our laboratory are now successful faculty members in other centers.
Program in Cancer Biology
Office: MDA 2SCR3.1030A (Unit 950)
M.D. - University of Alberta - 1977
Ph.D. - University of Alberta - 1984